Learning Center

Cell Therapy Manufacturing: Operational Strategies for Success

Cell Therapy Manufacturing: Strategy & Optimization

The course focuses on critical areas within the cell manufacturing workflow where inconsistencies and challenges frequently occur (e.g. Product Participants will benefit from real-world case studies presented by leading academic and industry experts from North America and Europe.

WHAT YOU WILL LEARN
  • Overview and applications of ICH guidelines in ATMP manufacturing processes
  • Recognize the importance of product characterization and Critical Quality Attributes (CQAs) in establishing specifications and ensuring product consistency (ICH Q8, ICH Q6B)
  • Apply risk-based thinking to identify and control Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) in ATMP manufacturing (ICH Q9)
  • Evaluate and select appropriate partners for scaling up, including developing contingency plans when vendors no longer support or exist
  • Compare and apply strategies for manufacturing scale-up and scale-out
  • Implement approaches to manage contamination risks when adopting new technologies or working with new suppliers
  • Understand the key time points in the product lifecycle where full analytical method validation is required to ensure data reliability, regulatory compliance, and product quality assurance
  • Defining characterization and potency from a regulatory perspective
  • Developing “linear-by-design” potency assay for absolute, non-relative quantification
  • Advantages and challenges of cryopreserving cell therapy products, and evaluating emerging technologies that improve cryopreservation quality, manufacturing consistency, and patient safety
  • Applicable regulatory requirements for performing critical assays on Human Cell, Tissue, or Cellular and Tissue-based Products (HCT/P)
DESIGNED FOR:


Key:

Complete
Failed
Available
Locked
Acknowledgement
Agree to terms to continue.
Agree to terms to continue. Non-Distribution Statement for Content and Exam Materials
Basis for Quality and Regulatory Requirements: An Overview
Lecture 1 Recording: Basis for Quality and Regulatory Requirements: An Overview
Open to view video.
Open to view video. Instructor: Anna Koptina, PhD Neogap Therapeutics, Excellerium AB Sweden
Lecture 1 Slide: Basis for Quality and Regulatory Requirements: An Overview
Open to download resource.
Open to download resource. Instructor: Anna Koptina Neogap Therapeutics, Excellerium AB Sweden
Cell Product Manufacturing Considerations: Analytical and Safety Testing
Lecture 2 Recording: Cell Product Manufacturing Considerations: Analytical and Safety Testing
Open to view video.
Open to view video. Instructors: Adrienne Mendoza, MHA Senior VP, BioBridge Global & Chief Operating Officer, BBG Advanced Therapies, United States
Lecture 2 Slide: Cell Product Manufacturing Considerations: Analytical and Safety Testing
Open to download resource.
Open to download resource. Instructors: Adrienne Mendoza, MHA Senior VP, BioBridge Global & Chief Operating Officer, BBG Advanced Therapies, United States
Cell Product Manufacturing Considerations: Cryopreservation, Stability, Storage, and Product Traceability
Lecture 3 Recording: Cell Product Manufacturing Considerations: Cryopreservation, Stability, Storage, and Product Traceability
Open to view video.
Open to view video. Instructor: Lindsay Davies, PhD Co-founder, QVance Sweden
Lecture 3 Slide: Cell Product Manufacturing Considerations: Cryopreservation, Stability, Storage, and Product Traceability
Open to download resource.
Open to download resource. Instructor: Lindsay Davies, PhD Co-founder, QVance Sweden
Cell Therapy Products: Potency Assays vs. Characterization – A Regulatory Perspective and Practical Approaches
Lecture 4 Recording: Cell Therapy Products: Potency Assays vs. Characterization – A Regulatory Perspective and Practical Approaches
Open to view video.
Open to view video. Instructors: Matthias Heemskerk, PhD Independent, former Head of Cell Therapy Analytical Development, Galapagos the Netherlands
Lecture 4 Slide: Cell Therapy Products: Potency Assays vs. Characterization – A Regulatory Perspective and Practical Approaches
Open to download resource.
Open to download resource. Instructors: Matthias Heemskerk, PhD Independent, former Head of Cell Therapy Analytical Development, Galapagos the Netherlands
Adapting to Emerging Technologies: Key Considerations, Scalability, and Limitations in Manufacturing
Lecture 5 Recording : Adapting to Emerging Technologies: Key Considerations, Scalability, and Limitations in Manufacturing
Recorded 05/26/2026  |  60 minutes
Recorded 05/26/2026  |  60 minutes Speaker: Melissa van Pel, PhD Head of Cell Therapy, NecstGen the Netherlands
Lecture 5 Slides: Adapting to Emerging Technologies: Key Considerations, Scalability, and Limitations in Manufacturing
Open to download resource.
Open to download resource. Speaker: Melissa van Pel, PhD Head of Cell Therapy, NecstGen the Netherlands
Course Evaluation
Course Evaluation Form
10 Questions
10 Questions For detailed information on how your data is retained, please refer to our program policies and guidelines using the below link in relation to Request for Record and Data Retrieval Policy and Our Privacy Policy: https://lms.isctglobal.org/Policies
Course Assessment
Summative Assessment
20 Questions  |  2 attempts  |  15/20 points to pass  |  Graded as Pass/Fail
20 Questions  |  2 attempts  |  15/20 points to pass  |  Graded as Pass/Fail There are a total of 15 questions associated with this exam. You must achieve a total score of 80% in order to pass. You have two attempts to complete the exam. Any of the course resources made available to you in the course modules may be used during this examination.
Certificate of Completion
No credits available  |  Certificate available
No credits available  |  Certificate available